IHH LEADS THE WAY IN ASIA'S CANCER CARE WITH MAIDEN PRIVATE PROTON THERAPY CENTRE LAUNCH

KUALA LUMPUR, May 15 (Bernama) -- IHH Healthcare, a world-leading integrated healthcare provider, has reinforced its position as Asia’s leading cancer care provider with the official opening of the Mount Elizabeth Proton Therapy Centre in Singapore.

Located in Mount Elizabeth Novena Hospital (MNH), the centre makes IHH the first private healthcare provider in the region and in Singapore to offer proton therapy, providing patients unprecedented access to this advanced and highly specialised cancer treatment.

IHH Healthcare Group Chief Executive Officer (CEO), Dr Prem Kumar Nair in a statement said adding proton therapy to IHH’s comprehensive suite of cancer treatment in Singapore solidified its standing as a Centre Of Excellence for oncology in Asia.

“Demand has already surpassed our expectations, and we are ramping up further to provide this cutting-edge treatment option to more patients across the region, as part of our purpose to touch lives and transform care,” he said.

Meanwhile, IHH Healthcare Singapore CEO, Dr Peter Chow said: “Cancer patients are not alone in their fight against cancer. IHH Healthcare Singapore’s investment in proton therapy demonstrates our unwavering resolve to provide our patients with the best care.

“Patients that are suited to undergo proton therapy will benefit from less side effects and damage to surrounding tissues due to the targeted nature of the proton beam.”

Proton therapy possesses unique properties that enable it to kill cancerous cells without causing as much damage to neighbouring tissue and organs, which means patients can better preserve function and enjoy higher long-term quality of life, which is especially critical and life-changing for younger patients.

The centre enhances MNH’s broad spectrum of oncology treatment modalities, including surgery, chemotherapy, and conventional radiotherapy, and is particularly beneficial for complex anatomical sites, sensitive tissues, as well as paediatric cases.

Since it began operations in May last year, the centre has treated more than 100 patients across 16 countries, from Singapore and Southeast Asia to as far as the United States, Canada and the United Kingdom, with patients ranging in ages from 18 months to 85 years.

-- BERNAMA